Education
About Us
Working with TipRanks
Follow Us
Neurocrine (NBIX)
NASDAQ:NBIX
NBIX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$93.59 - $157.98
Previous CloseN/A
Volume209.65K
Average Volume (3M)1.33M
Market Cap
$9.54B
Enterprise Value$13.47B
Total Cash (Recent Filing)$52.22M
Total Debt (Recent Filing)$10.53M
Price to Earnings (P/E)29.1
Beta0.77
Next Earnings
Apr 30, 2025EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.29
Shares Outstanding99,703,530
10 Day Avg. Volume1,361,217
30 Day Avg. Volume1,330,404
Financial Highlights & Ratios
PEG Ratio0.86
Price to Book (P/B)N/A
Price to Sales (P/S)4.74
Price to Cash Flow (P/CF)11.50
P/FCF Ratio11.50
Enterprise Value/Market Cap1.41
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.80
Enterprise Value/Ebitda22.07
Forecast
1Y Price Target
$163.60Price Target Upside75.44% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Neurocrine News
PremiumCompany Announcements
Neurocrine Biosciences Appoints Dr. Keswani as CMO---
Bulls Say, Bears Say
Bulls Say
Market PotentialSurveyed physicians indicated strong uptake of Crenessity over the next 2 years (could have dominant share within ~2-3 years on the market).
Product LaunchNBIX is highlighted for biotech investors given its well-established Ingrezza franchise and upside potential from the Crenessity CAH launch and pipeline programs.
Product SalesHigh margins on product sales offer some insulation to increased costs of goods sold.
Bears Say
Market Dynamics1Q sales will be impacted by increased commercial headwinds.
Sales ExpectationsStreet expectations for Crenessity's first-year sales are considered aggressive.
Sales Performance1Q sales for Ingrezza are expected to be impacted by increased commercial headwinds, including increased utilization management from payors and a slowdown in new scripts.
---
Ownership Overview
1.08% Insiders
24.91% Mutual Funds
24.62% Other Institutional Investors
20.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NBIX FAQ
What was Neurocrine’s price range in the past 12 months?
Neurocrine lowest stock price was $93.59 and its highest was $157.98 in the past 12 months.
What is Neurocrine’s market cap?
Neurocrine’s market cap is $9.54B.
When is Neurocrine’s upcoming earnings report date?
Neurocrine’s upcoming earnings report date is Apr 30, 2025 which is in 22 days.
How were Neurocrine’s earnings last quarter?
Neurocrine released its earnings results on Feb 06, 2025. The company reported $1 earnings per share for the quarter, missing the consensus estimate of $1.606 by -$0.606.
Is Neurocrine overvalued?
According to Wall Street analysts Neurocrine’s price is currently Undervalued.
Does Neurocrine pay dividends?
Neurocrine does not currently pay dividends.
What is Neurocrine’s EPS estimate?
Neurocrine’s EPS estimate is 0.73.
How many shares outstanding does Neurocrine have?
Neurocrine has 99,703,530 shares outstanding.
What happened to Neurocrine’s price movement after its last earnings report?
Neurocrine reported an EPS of $1 in its last earnings report, missing expectations of $1.606. Following the earnings report the stock price went down -18.53%.
Which hedge fund is a major shareholder of Neurocrine?
Currently, no hedge funds are holding shares in NBIX
---
Neurocrine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$163.60 (75.44% Upside)
$163.60 (75.44% Upside)
Blogger Sentiment
Bullish
NBIX Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $57.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 3.6%
Last 30 Days ▼ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.49%
12-Months-Change
Fundamentals
Return on Equity
14.16%
Trailing 12-Months
Asset Growth
15.53%
Trailing 12-Months
Company Description
Neurocrine
Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on developing and commercializing treatments for neurological and endocrine-related disorders. The company operates in the healthcare sector, leveraging innovative research to address unmet medical needs. Neurocrine's core products include INGREZZA (valbenazine), a medication for tardive dyskinesia, and ORILISSA (elagolix), developed in partnership with AbbVie for the treatment of endometriosis pain. The company's mission is to improve patient lives by delivering life-changing therapies through a commitment to scientific excellence and innovation.
---
NBIX Company Deck
---
NBIX Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted Neurocrine's strong performance in 2024 with record sales for INGREZZA and the successful launch of Quinicity. While there are challenges, such as increased competitive pressure and a measured launch for Quinicity, the company is taking proactive steps to address these issues. The overall sentiment is cautiously optimistic with a focus on growth and expansion in the neuroscience field.Read More>---
NBIX Stock 12 Month Forecast
Average Price Target
$163.60
▲(75.44% Upside)
Technical Analysis
Dr Reddy's Laboratories
―
Viatris
―
Perrigo Company
―
Teva Pharmaceutical
―
Intra-Cellular Therapies
―
Best Analysts Covering NBIX
1 Year
1 Year Success Rate
17/29 ratings generated profit
1 Year Average Return
+6.86%
reiterated a buy rating 5 months ago
Copying Brian Skorney's trades and holding each position for 1 Year would result in 58.62% of your transactions generating a profit, with an average return of +6.86% per trade.
---